Mazdutide vs Retatrutide
Glucagon dual vs glucagon-containing triple
Both mazdutide and retatrutide (nicknamed "Reta") use glucagon receptor agonism for energy expenditure and liver-fat reduction — but retatrutide adds GIP to become a triple agonist. Here is how the dual and the triple compare on mechanism, data, and stage.
Two glucagon-driven drugs, one extra receptor
Mazdutide (Innovent/Lilly) is a GLP-1/glucagon dual agonist; retatrutide (Eli Lilly) is a GLP-1/GIP/glucagon triple agonist. They share the glucagon component — which raises energy expenditure and reduces liver fat — but retatrutide adds GIP, layering on extra appetite and metabolic effects that have produced the deepest weight loss recorded in obesity trials.
Mazdutide is furthest along in China with Phase 3 data, while retatrutide reported a positive Phase 3 readout (TRIUMPH-4) with up to 28.7% mean weight loss at 68 weeks. Both are investigational outside their current settings, and they have never been tested against each other.
Mazdutide vs Retatrutide at a glance
- ⚡Mechanism: GLP-1 + glucagon dual agonist
- ⚡Phase 3 weight loss reported in China’s GLORY program
- ⚡Glucagon adds energy expenditure and liver-fat reduction
- ⚡Furthest along in China; investigational elsewhere
- ⚡Simpler dual mechanism than a triple agonist
- ✓Mechanism: GLP-1 + GIP + glucagon triple agonist
- ✓Phase 3 TRIUMPH-4: up to 28.7% mean weight loss at 68 weeks
- ✓Adds GIP on top of glucagon for deeper effect
- ✓Investigational, Phase 3 ongoing globally
- ✓Largest reported weight loss in obesity trials so far
Which is the one to watch?
Retatrutide is the deeper-weight-loss, further-along (globally) candidate, with the GIP component adding to its glucagon base. Mazdutide is the simpler glucagon dual, most relevant in China, and may appeal where it is approved or for those preferring a dual over a triple agonist.
Because both rely on glucagon, they share a focus on energy expenditure and liver fat — but retatrutide’s triple mechanism is what has driven its record numbers.
Track now, compare later
With no head-to-head trial, your own response is the most useful data for a future decision. Logging weight, appetite, side effects, and labs in Shotlee builds an objective baseline so you can compare with precision if either drug becomes available.
Use this comparison as a framework and confirm specifics with your healthcare provider.
Mazdutide vs Retatrutide: Frequently Asked Questions
Retatrutide has reported deeper weight loss (up to 28.7% in Phase 3) thanks to its triple GLP-1/GIP/glucagon mechanism, while mazdutide is a GLP-1/glucagon dual. There is no head-to-head trial, so the comparison is directional, and both are investigational in most markets.
Both include glucagon agonism, but mazdutide is a dual (GLP-1 + glucagon) and retatrutide is a triple (GLP-1 + GIP + glucagon). Retatrutide’s added GIP is associated with its larger weight loss.
Mazdutide is furthest along in China; retatrutide is in Phase 3 globally. Neither is broadly approved or available outside trials and specific markets.
Both use glucagon agonism, which is associated with increased energy expenditure and reduced liver fat, making them of interest for metabolic liver disease. This is investigational and should involve a specialist.
Yes. Shotlee logs doses, weight, side effects, and labs for your current protocol, free — ready to compare if you change medications.
Track Your Protocol in Shotlee
Free dose logging, weight trends, lab snapshots, and side effect tracking.
